Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 8/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631629 | 0.93 | NTSR1 (0.68) | NTSR1GRIN2BFTOEGLN1EGLN3 | |
| SCHEMBL23631656 | 0.79 | NTSR1 (0.46) | NTSR1KMT2A | |
| SCHEMBL23631632 | 0.79 | NTSR1 (0.67) | NTSR1KMT2A | |
| SCHEMBL6138108 | 0.78 | KMT2A (0.69) | NTSR1KMT2A | |
| SCHEMBL23631570 | 0.76 | KDM4E (0.52) | NTSR1GRIN2BKMT2A | |
| SCHEMBL23631615 | 0.76 | NTSR1 (0.47) | NTSR1GRIN2BMGLL | |
| SCHEMBL31602786 | 0.76 | KMT2A (0.65) | NTSR1KMT2A | |
| SCHEMBL23631580 | 0.75 | NTSR1 (0.51) | NTSR1 | |
| SCHEMBL23631648 | 0.74 | NTSR1 (0.60) | NTSR1KMT2A | |
| SCHEMBL3599423 | 0.73 | NTSR1 (0.56) | NTSR1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | claimed |
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | UNIV NEW YORK (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214359-A1 | Compounds and Methods for Treating Bacterial Infections | CBS, MPO, QSOX1 | NTSR1 2656/4885GRIN2B 3925/4885FTO 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.